United Therapeutics (UTHR) Insider Trading & Ownership $314.56 +3.52 (+1.13%) (As of 07/5/2024 ET) Add Compare Share Share Insider TradesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends United Therapeutics (NASDAQ:UTHR) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage12.50%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)5Amount OfInsider Selling(Last 12 Months)$69.84 M UTHR Insider Buying and Selling by Quarter Ad Chaikin Analytics50-year Wall Street Legend Issues July Stock WarningJuly is historically the best month of the year for U.S. stocks. So why are everyone’s favorite tech stocks – including NVDA – stumbling?To see this July stock warning for yourself – 100% free – click here. United Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails7/3/2024Martine A RothblattCEOSell3,600$312.48$1,124,928.00 7/1/2024Martine A RothblattCEOSell3,600$320.45$1,153,620.00 6/27/2024Martine A RothblattCEOSell3,600$316.62$1,139,832.00 6/25/2024Nilda MesaDirectorSell266$318.58$84,742.28 6/24/2024Martine A RothblattCEOSell3,600$315.97$1,137,492.00 6/21/2024Martine A RothblattCEOSell3,600$313.91$1,130,076.00 Top Hedge Funds Reveal A.I. Moonshot Coins (Ad)The manager of top crypto hedge fund Pantera recently said every crypto company will soon be an artificial intelligence venture… And there are a handful of little-known crypto projects in the A.I. sector that they expect to benefit the most during this wave. Click here to reserve your seat now.6/14/2024Martine A RothblattCEOSell3,600$287.22$1,033,992.00 6/13/2024Christopher CauseyDirectorSell2,000$281.53$563,060.00 6/12/2024Martine A RothblattCEOSell3,600$281.19$1,012,284.00 6/10/2024Martine A RothblattCEOSell3,600$273.95$986,220.00 6/7/2024Martine A RothblattCEOSell3,600$277.13$997,668.00 5/31/2024Martine A RothblattCEOSell3,600$272.48$980,928.00 5/28/2024Martine A RothblattDirectorSell3,600$269.06$968,616.00 5/23/2024Martine A RothblattDirectorSell3,600$275.78$992,808.00 5/21/2024Martine A RothblattDirectorSell1,468$275.85$404,947.80 5/16/2024Martine A RothblattDirectorSell3,600$272.37$980,532.00 5/14/2024Christopher PatuskyDirectorSell1,310$264.35$346,298.50 5/13/2024Martine A RothblattCEOSell3,600$265.48$955,728.00 5/9/2024Martine A RothblattCEOSell3,600$264.22$951,192.00 5/6/2024Martine A RothblattCEOSell3,600$259.70$934,920.00 5/3/2024Christopher CauseyDirectorSell2,240$259.91$582,198.40 5/2/2024Martine A RothblattCEOSell3,600$258.09$929,124.00 4/30/2024Martine A RothblattCEOSell3,600$235.35$847,260.00 4/26/2024Martine A RothblattCEOSell3,600$235.20$846,720.00 4/24/2024Martine A RothblattCEOSell3,600$238.81$859,716.00 4/22/2024Martine A RothblattCEOSell3,600$236.47$851,292.00 4/18/2024Martine A RothblattCEOSell3,600$237.91$856,476.00 4/16/2024Martine A RothblattCEOSell3,600$232.05$835,380.00 4/12/2024Martine A RothblattCEOSell3,600$235.42$847,512.00 4/10/2024Martine A RothblattCEOSell13,800$237.27$3,274,326.00 4/8/2024Martine A RothblattCEOSell5,060$237.52$1,201,851.20 4/4/2024Martine A RothblattCEOSell15,000$233.27$3,499,050.00 4/4/2024Paul A MahonEVPSell6,000$232.37$1,394,220.00 3/28/2024Martine A RothblattCEOSell14,125$236.18$3,336,042.50 3/27/2024Nilda MesaDirectorSell325$237.80$77,285.00 3/26/2024Martine A RothblattCEOSell15,000$248.33$3,724,950.00 3/22/2024Martine A RothblattCEOSell15,000$237.05$3,555,750.00 3/21/2024Paul A MahonEVPSell6,000$236.45$1,418,700.00 3/19/2024Martine A RothblattCEOSell15,000$236.59$3,548,850.00 2/23/2024Christopher PatuskyDirectorSell1,680$224.00$376,320.00 50-year Wall Street Legend Issues July Stock Warning (Ad)July is historically the best month of the year for U.S. stocks. So why are everyone’s favorite tech stocks – including NVDA – stumbling?To see this July stock warning for yourself – 100% free – click here.2/15/2024Paul A MahonEVPSell6,000$215.31$1,291,860.00 2/1/2024Paul A MahonEVPSell6,000$215.01$1,290,060.00 1/18/2024Paul A MahonEVPSell6,000$218.72$1,312,320.00 1/4/2024Paul A MahonEVPSell6,000$227.97$1,367,820.00 12/21/2023Paul A MahonEVPSell6,000$229.27$1,375,620.00 12/19/2023Nilda MesaDirectorSell605$244.90$148,164.50 12/12/2023Christopher CauseyDirectorSell3,000$249.68$749,040.00 12/7/2023Paul A MahonEVPSell6,000$238.89$1,433,340.00 11/2/2023Paul A MahonEVPSell6,000$225.76$1,354,560.00 10/19/2023Paul A MahonEVPSell6,000$225.43$1,352,580.00 10/5/2023Paul A MahonEVPSell6,000$223.82$1,342,920.00 9/21/2023Paul A MahonEVPSell6,000$222.19$1,333,140.00 9/13/2023Nilda MesaDirectorSell383$222.36$85,163.88 9/7/2023Paul A MahonEVPSell6,000$222.98$1,337,880.00 8/3/2023Paul A MahonEVPSell6,000$236.25$1,417,500.00 7/20/2023Paul A MahonEVPSell2,500$243.87$609,675.00 7/6/2023Paul A MahonEVPSell6,000$215.19$1,291,140.00 (Data available from 1/1/2013 forward) UTHR Insider Trading Activity - Frequently Asked Questions Who is on United Therapeutics's Insider Roster? The list of insiders at United Therapeutics includes Christopher Causey, Christopher Patusky, Judy D Olian, Louis W Sullivan, Martine A Rothblatt, Nilda Mesa, Paul A Mahon, and Raymond Dwek. Learn more on insiders at UTHR. What percentage of United Therapeutics stock is owned by insiders? 12.50% of United Therapeutics stock is owned by insiders. Learn more on UTHR's insider holdings. Which United Therapeutics insiders have been buying company stock? The following insider purchased UTHR shares in the last 24 months: Christopher Patusky ($684.36). How much insider buying is happening at United Therapeutics? Insiders have purchased a total of 6 UTHR shares in the last 24 months for a total of $684.36 bought. Which United Therapeutics insiders have been selling company stock? The following insiders have sold UTHR shares in the last 24 months: Christopher Causey ($2,681,658.40), Christopher Patusky ($723,157.05), Judy D Olian ($284,820.00), Louis W Sullivan ($883,639.60), Martine A Rothblatt ($147,324,632.00), Nilda Mesa ($732,972.40), Paul A Mahon ($46,412,862.12), and Raymond Dwek ($521,186.40). How much insider selling is happening at United Therapeutics? Insiders have sold a total of 815,403 United Therapeutics shares in the last 24 months for a total of $199,564,927.97 sold. More Insider Trading Tools from MarketBeat Related Companies: TEVA Insider Selling BPMC Insider Selling BBIO Insider Selling PRGO Insider Selling ARWR Insider Selling BHVN Insider Selling BHC Insider Selling BIIB Insider Selling ALNY Insider Selling BMRN Insider Selling Insider Tracking Tools: CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country: U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles: 3 Stock Dips Insiders Are Buying: Vestis, Shenandoah, TreaceIs CAVA Overextended? A Closer Look at This High-Flying StockOccidental Petroleum: Buffett Causes OXY Stock Rebound3 Tech Stocks Insiders, Major Shareholders, and Institutions BuyThe Top 3 Stocks Sold by Insiders This Quarter This page (NASDAQ:UTHR) was last updated on 7/6/2024 by MarketBeat.com Staff From Our PartnersWhy Conservative Americans Are Turning to Gold in 2024Welcome to the financial rollercoaster of 2024, where inflation is relentless, stock markets are inflated, and...All American Assets | Sponsored50-year Wall Street Legend Issues July Stock WarningJuly is historically the best month of the year for U.S. stocks. So why are everyone’s favorite tech stocks...Chaikin Analytics | SponsoredBiden to drop out; finish out his term?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in...Paradigm Press | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredNvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.Weiss Ratings | SponsoredSilver Expected for Extreme Price ActionOur newest Silver Investing Guide reveals how savvy investors are capitalizing on silver's continued rise – PL...Colonial Metals | Sponsored1k a day while computer does all work?What I discovered is now helping me take in more than 1k a day. It's like a "magic key" to passive income ...Digital Mavericks Media | SponsoredBill Gates is all about this tiny $2 stockWhat does Bill Gates know about this tiny company that we don’t? From the outside, it looks like a worthles...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist My Default Watchlist Adding United Therapeutics Co. You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Share United Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
